

# The Neo-ACT trial

## Newsletter, November 2023

Jana de Boniface, Cecilia Ringborg, Renske Altena, Yvonne Wengström and Marie Westman



### Inclusion is up and running

Neo-ACT has randomized 57 patients in Sweden and Finland so far!

### International expansion

The expansion of the trial to further international sites via different networks, e.g., EUBREAST (European Breast Cancer Research Association of Surgical Trialists) is ongoing. English-speaking and German-speaking countries will be the first in line to join the trial, potentially followed by further countries and languages in due course.

### Translation of Vitala app into German

The Vitala app is currently available in Swedish and English. The process to translate the Vitala app into German has been initiated.

### Multiple German sites planned for participation from spring 2024

Once negotiations with the German Clinical Research Organization that will handle study administration and monitoring for German-speaking sites are completed, trial participation can be opened at German and German-speaking Swiss sites.

### Participation of sites in English-speaking countries

Hopefully, we can soon welcome sites in Scotland (Edinburgh and Glasgow), the UK (Royal Marsden), and Australia (Melbourne) to the trial. Discussions are ongoing regarding trial structure, logistics and set-up.


### Exciting publication

The Journal of Clinical Oncology recently published the results of the LEANer study by Sanft et al, corroborating the hypothesis of exercise – here combined with a dietary intervention – improving pCR rates. In a randomized trial including 173 women with breast cancer, the secondary outcome pCR was 53% in those assigned to exercise and diet, as compared with 28% in those receiving usual care. A real boost for the Neo-ACT trial and a thumbs-up for our hypothesis!



### Patient reimbursement increased

The site reimbursement per patient will increase to 600 Euro / 450 GBP from January 2024.



### Homepage

For any purposes and needs, please visit our trial homepage.

<https://ki.se/en/mmk/the-neo-act-trial>

Contact:

Trial management

[marie.westman@cytel.com](mailto:marie.westman@cytel.com)



Kind regards,  
The Neo-ACT Team